Full Press Release Details
Inc.'s Subsidiary OncoCyte Corporation's CEO Dr. Joseph Wagner to
Present at BTIG's Inaugural "Emerging Technologies in Healthcare
Diagnostics" Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--September 19, 2014--OncoCyte
Corporation, a subsidiary of BioTime, Inc. (NYSE MKT: BTX), today
announced that Chief Executive Officer Joseph Wagner, Ph.D. is scheduled
to present at the inaugural BTIG Emerging Technologies in Healthcare
Diagnostics Symposium being held September 29-30, 2014 at The Benjamin
Hotel in New York City. As part of the symposium, leading diagnostic
companies will present on a series of thematic panels to familiarize
attendees with the diagnostic space, associated technologies, and foster
an understanding of how the tools work and why they should be adopted.
Participants in the conference include publicly-traded companies as well
as companies that, like OncoCyte, are not yet publicly traded.
During the symposium, Dr. Wagner will participate on two thematic
panels. The first panel, entitled "Symptomatic Oncology - Innovations in
Blood Testing" will convene at 1:10 PM on Monday, September 29. The
second panel, entitled "Changing Screening Paradigms from Scratch" will
convene at 3:40 PM on Tuesday, September 30. During the presentations
and as part of the ensuing discussions, Dr. Wagner may provide an update
on the clinical development of OncoCyte's PanC-Dx
products. In addition to his appearance at the conference, Dr. Wagner
will also be meeting with investors in other meetings in New York
beginning next week. BioTime plans to file a Form 8-K with the
Securities and Exchange Commission next week that will include the
OncoCyte presentation materials that will be used in these investor
PanC-Dx is a class of non-invasive cancer diagnostics
based on OncoCyte's proprietary set of cancer markers, which were
discovered by company scientists through an analysis of broad gene
expression patterns in numerous cancer types. OncoCyte is currently
sponsoring four clinical studies of PanC-Dx in bladder, breast,
and lung cancer, of which approximately 1300, 800 and 750 subjects are
expected to be enrolled, respectively. The data on the majority of these
studies is expected to be collected and analyzed by the end of 2014.
About OncoCyte Corporation
OncoCyte, a majority-owned subsidiary of BioTime, Inc., is developing
novel products for the diagnosis and treatment of cancer in order to
improve the quality and length of life of cancer patients. Based on
large unmet need, market size, and data generated thus far from patient
sample screening, OncoCyte is initially focusing its efforts on
developing PanC-Dx diagnostic products for use in detecting
breast, bladder, and lung cancers. PanC-Dx is a class of
non-invasive cancer diagnostics based on a proprietary set of cancer
markers characterized, in part, by broad gene expression patterns in
numerous cancer types. The PanC-Dx biomarkers were discovered as
a result of ongoing research within OncoCyte and BioTime on the gene
expression patterns associated with embryonic development. This research
has demonstrated that many of the same genes associated with normal
growth during embryonic development are abnormally reactivated by cancer
cells. These genes regulate such diverse processes as cell
proliferation, cell migration and blood vessel formation. Many of these
genes have not been previously associated with cancer. Moreover,
expression of a large subset of these genes is conserved across numerous
cancer types (e.g. cancers of the breast, colon, ovaries, etc.),
suggesting these genes may control fundamental processes during cancer
growth and progression. In addition to their potential value in
developing diagnostic biomarkers, an understanding of the pattern of
expression of these genes may also enable the development of powerful
new cancer therapeutics that target rapidly proliferating cancer cells.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime's focus is on pluripotent stem cell technology based on
human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime's
therapeutic and research products include a wide array of proprietary PureStem
progenitors, HyStem hydrogels, culture media,
and differentiation kits. BioTime is developing Renevia (a HyStem
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications, and is planning
to initiate a pivotal clinical trial around Renevia , in 2014. In
addition, BioTime has developed Hextend , a blood
plasma volume expander for use in surgery, emergency trauma treatment
and other applications. Hextend is manufactured
and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
HealthCare Corporation, under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
Asterias Biotherapeutics, Inc. is developing pluripotent
stem-cell based therapies in neurology and oncology, including
AST-OPC1 oligodendrocyte progenitor cells in spinal cord injury,
multiple sclerosis and stroke, and AST-VAC2, an allogeneic dendritic
cell-based cancer vaccine. Asterias trades publicly under the symbol
BioTime Asia, Ltd., a Hong Kong company, may offer and sell
products for research use for BioTime's ESI BIO Division.
Cell Cure Neurosciences Ltd. is an Israel-based biotechnology
company focused on developing stem cell-based therapies for retinal
and neurological disorders, including the development of retinal
pigment epithelial cells for the treatment of macular degeneration,
and treatments for multiple sclerosis.
ESI BIO is the research and product marketing division of
BioTime, providing stem cell researchers with products and
technologies to enable them to translate their work into the clinic,
including PureStem progenitors and HyStem
LifeMap Sciences, Inc. markets, sells, and distributes GeneCards ,
the leading human gene database, as part of an integrated database
suite that also includes the LifeMap Discovery